Patents by Inventor Arie Dagan

Arie Dagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9447040
    Abstract: Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: September 20, 2016
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Shmuel Ben-Sasson, Arie Dagan, Sharon Perles
  • Patent number: 9340488
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 17, 2016
    Assignees: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavy
  • Publication number: 20150183721
    Abstract: This invention relates to amino-alcohol analogues and uses thereof in the treatment of diseases and disorders such as cancer, neurodegenerative and metabolic diseases and genetic storage diseases.
    Type: Application
    Filed: March 17, 2015
    Publication date: July 2, 2015
    Inventors: Arie DAGAN, Claudia M. BARZILAY, Amona A. ALI
  • Publication number: 20150073003
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Arie DAGAN, Shimon SLAVIN, Shimon GATT, Jeremy ZAHAVY
  • Patent number: 8962891
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Grant
    Filed: November 9, 2008
    Date of Patent: February 24, 2015
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
  • Publication number: 20140329877
    Abstract: Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 6, 2014
    Inventors: Shmuel Ben-Sasson, Arie Dagan, Sharon Perles
  • Patent number: 8592394
    Abstract: The invention relates to novel synthetic derivatives of ?-glycolipids and uses thereof as immunomodulators. More particularly, the invention relates to synthetic derivatives of ?-glycolipids, specifically, the compounds of any one of Formula I, II III and IV or any mixture or combination thereof, and particularly the ALIB-97 (Formula II) derivative and uses thereof for the treatment of different pathologic disorders, particularly, immune-related hepatic disorders and pathologies associated with the metabolic syndrome.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: November 26, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Arie Dagan
  • Publication number: 20130079305
    Abstract: 3-substituted vinylboronates and their use in the treatment of cancer such as colorectal cancer are disclosed. In some embodiments, the 3-substituted vinylboronates have the general Formula I: with the variables in the formula being as defined in the specification.
    Type: Application
    Filed: May 31, 2011
    Publication date: March 28, 2013
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Morris Srebnik, Abed Al-Aziz Quntar, Alina Botvinik, Arie Dagan
  • Publication number: 20120129947
    Abstract: This invention relates to amino-alcohol analogues and uses thereof in the treatment of diseases and disorders such as cancer, neurodegenerative and metabolic diseases and genetic storage diseases.
    Type: Application
    Filed: August 3, 2010
    Publication date: May 24, 2012
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Arie Dagan, Claudia M. Barzilay, Amona A. Ali
  • Publication number: 20110071100
    Abstract: The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine.
    Type: Application
    Filed: May 5, 2009
    Publication date: March 24, 2011
    Applicant: TILTAN PHARMA LTD.
    Inventors: Shmuel A. Ben-Sasson, Arie Dagan
  • Publication number: 20110034542
    Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
    Type: Application
    Filed: November 9, 2008
    Publication date: February 10, 2011
    Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
  • Publication number: 20100311841
    Abstract: Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.
    Type: Application
    Filed: November 6, 2008
    Publication date: December 9, 2010
    Inventors: Arie Dagan, Shimon Gatt, Shimon Slavin
  • Publication number: 20100221358
    Abstract: The invention relates to novel synthetic derivatives of ?-glycolipids and uses thereof as immunomodulators. More particularly, the invention relates to synthetic derivatives of ?-glycolipids, specifically, the compounds of any one of Formula I, II III and IV or any mixture or combination thereof, and particularly the ALIB-97 (Formula II) derivative and uses thereof for the treatment of different pathologic disorders, particularly, immune-related hepatic disorders and pathologies associated with the metabolic syndrome.
    Type: Application
    Filed: October 13, 2009
    Publication date: September 2, 2010
    Inventors: Yaron Ilan, Arie Dagan
  • Patent number: 7056653
    Abstract: The extent of binding of a moiety, such as a biomolecule, to a surface, where the local environment at the surface has a pH or surface potential which is altered upon binding of the moiety, is determined by stably incorporating at the surface a probe which contains a pH- or potential-sensitive fluorophore.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: June 6, 2006
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Danielle Hirsch-Lerner, Rivka Cohen, Arie Dagan, Shimon Gatt
  • Patent number: 6630309
    Abstract: Binding between two members of a recognition pair, e.g. antigen-antibody is determined by utilizing a probe which includes a piezoelectric crystal with electrodes on two opposite faces of the crystal. The crystal carries one or more metal plates which may be the same or different than the electrodes, the metal plates having immobilized thereon a first member of a recognition pair. Binding of a second member of the recognition pair to the first member, or dissociation between the two members and release of the second member from the probe, causes a change of immobilized mass which results in a change to the probe's resonance frequency.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: October 7, 2003
    Assignees: Biosensor Applications Sweden AB, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Itamar Willner, Shlomo Levi, Yael Cohen, Eugenii Katz, Arie Dagan
  • Publication number: 20020028440
    Abstract: Binding between two members of a recognition pair, e.g. antigen-antibody is determined by utilizing a probe comprising a piezoelectric crystal with electrodes on two opposite faces of the crystal. The crystal carries one or more metal plates which may be the same or different than said electrodes, the metal plates having immobilized thereon a first member of a recognition pair. Binding of a second member of the recognition pair to the first member, or dissociation between the two members and release of the second member from the probe, causes a change of immobilized mass which results in a change to the probe's resonance frequency.
    Type: Application
    Filed: June 4, 1998
    Publication date: March 7, 2002
    Inventors: ITAMAR WILLNER, SHLOMO LEVI, YAEL COHEN, EUGENII KATZ, ARIE DAGAN
  • Publication number: 20020012923
    Abstract: The extent of binding of a moiety, such as a biomolecule, to a surface, where the local environment at the surface has a pH or surface potential which is altered upon binding of the moiety, is determined by stably incorporating at the surface a probe which contains a pH- or potential-sensitive fluorophore.
    Type: Application
    Filed: February 8, 2001
    Publication date: January 31, 2002
    Inventors: Yechezkel Barenholz, Danielle Hirsch-Lerner, Rivka Cohen, Arie Dagan, Shimon Gatt
  • Patent number: 6028102
    Abstract: According to the present invention, anticonvulsant compounds N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide are disclosed. The present invention also discloses an anticonvulsant pharmaceutical composition comprising an effective amount of at least one active ingredient selected from N-acetyl,N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide and a pharmaceutically acceptable carrier or diluent. The present invention provides a method of controlling convulsions in a mammal by administering to the mammal an effective amount of antiepileptic compounds N-acetyl,N'-benzylglycinamide or N-benzyloxycarbonylglycinamide-Z-glycinamide. Combinations of the anticonvulsion compounds can also be administered. The convulsions may be due to epilepsy, febrile convulsions or convulsions precipitated by irritative lesions in the brain. Further the composition may be used to prevent migraine and to treat chronic pain and bipolar disorder.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: February 22, 2000
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Meir Bialer, Arie Dagan, Sussan Sherbel
  • Patent number: 5942388
    Abstract: An elcctrobiochemical system for the determination of the presence and optionally concentration of an analyte in a liquid medium, the system comprising an electrode having immobilized thereon a member of a recognition pair, the other member of said pair being said analyte, the presence of said analyte in the medium resulting in formation of a pair complex, being a complex between said immobilized member and said analyte; the system further comprising redox molecules capable of changing their redox state by accepting electrons from or donating electrons to the electrode; the formation of the pair complex on the electrode bringing a change in the electrical response of the system, whereby the presence and optionally the concentration of said analyte in the medium can be determined.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: August 24, 1999
    Assignee: Yissum Research Development Company of the Hebrew University of Jersaleum
    Inventors: Itamar Willner, Arie Dagan, Shai Rubin, Ron Blonder, Azalia Riklin, Yael Cohen
  • Patent number: 5492924
    Abstract: Phorbine derivatives having high potency and light absorptivity in the 650 to 780 nanometer range are useful in cancer diagnosis and therapy, especially photodynamic therapy.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: February 20, 1996
    Assignees: Fox Chase Cancer Center, The French National Institute of Health and Medical Research (Inserm), Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Shimon Gatt, Arie Dagan, Rene Santus, Jean-Claude Maziere, J. Donald Chapman, Edward L. Engelhardt